Tivozanib is a kinase inhibitor to treat adult patients with renal cell carcinoma (RCC) who have failed prior systemic therapies or experienced relapsed disease. Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults.
- Mechanism
- Curator reviewed · 3 references
The VHL mutation-HIF upregulation-VEGF transcription is the main pathway implicated in the growth of renal cell carcinoma. Vascular endothelial growth factor receptors (VEGFR receptors) are important targets for tyrosine kinase inhibitors, which halt the growth of tumours. Tivozanib is a tyrosine kinase inhibitor that exerts its actions by inhibiting the phosphorylation of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3 and inhibits other kinases such as c-kit and platelet derived growth factor beta (PDGFR β). The above actions inhibit tumour growth and progression, treating renal cell carcinoma.
- Primary indication
- Tivozanib is approved in the USA for the treatment of relapsed or refractory renal cell carcinoma in adult patients who have undergone two or more systemic therapies.Curator reviewed · 4 structured indications
- Formula / weight
- C22H19ClN4O5 · 454.863 g/mol (avg)
- First approval
- United States, 2021 · European Union, 2020
- Code names
- AV-951 · KIL-8951 · KRN-951
- Brand names
Resolves to
SPMVMDHWKHCIDT-UHFFFAOYSA-NSMILESCOC1=C(OC)C=C2C(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=CC=NC2=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Tivozanib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account